What does this research mean for the field?

Finerenone reduces total heart failure events and cardiovascular death in patients with mildly reduced or preserved ejection fraction regardless of heart failure severity, offering larger absolute rate reductions in severe heart failure. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

November 4, 2025European Journal of Heart FailureOpen Access

Finerenone in Patients with Severe Heart Failure: The FINEARTS-HF Trial

View Full Paper

Ask AI

Bookmark

Why the study?

Severe heart failure occurs across the full spectrum of LVEF, prompting evaluation of its prevalence, cardiovascular risk, and response to finerenone in FINEARTS-HF.

Does finerenone reduce total HF events and CV death in patients with mildly reduced or preserved LVEF, including those with severe HF?

Structured PICO

Does finerenone reduce total HF events and CV death in patients with mildly reduced or preserved LVEF, including those with severe HF?

Population

Patients with mildly reduced or preserved LVEF, including 888 (14.8%) with severe HF defined by adapted multiparametric ESC-HFA criteria (NYHA class III/IV, hospitalization for HF within the previous 12 months, and KCCQ total symptom score <75).

Intervention

Finerenone

Outcome

Total (first and recurrent) HF events and CV deathcomposite

Finerenone safely and effectively reduces cardiovascular events in patients with mildly reduced or preserved LVEF, providing a greater absolute risk reduction in those with severe heart failure.

Implication

Supports finerenone in severe HFmrEF/HFpEF; extends efficacy to higher-risk subgroups with consistent relative benefit.

Abstract

Aims While patients with severe heart failure (HF) were historically considered to have reduced left ventricular ejection fraction (LVEF), it is increasingly recognized that severe HF occurs across the full spectrum of LVEF. The aim of this study was to assess prevalence, cardiovascular (CV) outcome risk, and treatment response to the non-steroidal mineralocorticoid receptor antagonist finerenone among patients with severe HF in FINEARTS-HF. Methods and results Treatment effects of finerenone on the primary endpoint of total (first and recurrent) HF events and CV death were assessed by severe HF status, as defined by the adapted multiparametric ESC-HFA criteria including New York heart Association functional class III/IV, hospitalization for HF within the previous 12 months, and impairment of health status measured by Kansas City Cardiomyopathy Questionnaire total symptom score <75. Overall, 888 (14.8%) patients fulfilled the definition for severe HF. Patients with severe HF were older, with a higher comorbidity burden, and higher N-terminal pro-B-type natriuretic peptide levels. Over a median follow-up of 2.7 years, total HF events and CV death occurred at a higher rate among those with severe HF (31.6 per 100 patient-years [py]) as compared to those without severe HF (13.9 per 100py). Finerenone was beneficial in reducing the rate of the primary endpoint regardless of severe HF status (pinteraction = 0.98), with a greater absolute rate reduction in those with severe HF (5.9 per 100py) compared with those without severe HF (2.2 per 100py) in light of higher baseline risk. The proportion of patients who discontinued study treatment for any reason or experienced adverse events according to treatment assignment was similar regardless of severe HF status. Conclusions Among patients with mildly reduced or preserved LVEF, severe HF was associated with a heightened risk of CV events. Treatment with finerenone appeared safe and effective, regardless of HF severity.